Brind.

Hengrui Pharma is developing obesity treatments, with Su Zhang leading non-oncology clinical development at the company.

1 report, 1 independent Updated Jun 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Hengrui Pharma is developing obesity treatments, with Su Zhang leading non-oncology clinical development at the company.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

  • Hengrui

    Republic of China person CBDB = 91660

    Nothing else this week.

Coverage

Newest first; wire copies grouped